Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000CHP2222
Wed, 17.07.2024
Cheplapharm AG
Artem Gevorkyan joins as Managing Director Corporate Business Development
Karl ‘Charly’ Lang is entrusted with an extended area of responsibility and now leads the Supply Chain & Logistics division across the whole Group
Klaus Köhl, previously COO, is leaving the company at his own request
The globally active CHEPLAPHARM Group, headquartered [ … ]
Fri, 26.04.2024
Cheplapharm AG
CHEPLAPHARM CLOSES FINANCIAL YEAR 2023 WITH RECORD REVENUE AND DOUBLE-DIGIT GROWTH
Greifswald, 26th April 2024
Double-digit revenue growth again: +17% YoY to € 1,498.4 million (FY2022: € 1,279.5 million)
EBITDA increases significantly by +14% YoY to € 780.5 million (FY2022: € 685.7 million)
EBITDA margin remains at a high and industry-leading le [ … ]
Wed, 03.04.2024
Cheplapharm AG
Greifswald / Levallois-Perret, 03. April 2024Caroline Jacquin will take over the management of CHEPLAPHARM France, based in Levallois-Perret, a subsidiary of the CHEPLAPHARM Group from Greifswald/Germany, in April 2024. The previous Managing Director of CHEPLAPHARM France, Isabelle Dalle, is retiring.
Caroline Jacquin, an experienced pharmaceutica [ … ]
Thu, 18.01.2024
Cheplapharm AG
Binningen, January 18, 2024
The CHEPLAPHARM Group acquires the global rights to Roaccutane® from Roche, thereby strengthening its dermatological portfolio. The medicine, which is based on the active ingredient isotretinoin, is used to treat severe acne.
CHEPLAPHARM, a leading purchaser of originator products from research-based pharmaceutic [ … ]
Mon, 06.11.2023
Cheplapharm AG
Greifswald / Tokyo, 6 November 2023
CHEPLAPHARM Arzneimittel GmbH, based in Greifswald/Germany, has opened a presence in the Japanese capital Tokyo and obtained the pharmaceutical licence for Japan. With this, CHEPLAPHARM meets the requirements to be a Marketing Authorisation Holder in Japan. The managing director of the founded CHEPLAPHARM KK i [ … ]
Thu, 21.09.2023
Cheplapharm AG
EQS-Media / 21.09.2023 / 13:41 CET/CEST
CHEPLAPHARM Arzneimittel GmbH (“CHEPLAPHARM” or the “Company”), a leading international platform for well-established branded medicines, took advantage of the currently favorable market conditions and successfully placed additional senior secured notes with a total volume of €300m. [ … ]
Tue, 12.09.2023
Cheplapharm AG
Agnes Wasem is the Managing Director of the newly founded CHEPLAPHARM Schweiz GmbH
CHEPLAPHARM Arzneimittel GmbH, headquartered in Greifswald/Germany, has established a Swiss national subsidiary in Binningen. Managing Director of the newly founded CHEPLAPHARM Schweiz GmbH is Agnes Wasem. Wasem has already held the position since August 1, 2023, an [ … ]
Fri, 28.04.2023
Cheplapharm AG
CHEPLAPHARM Arzneimittel GmbH (“CHEPLAPHARM”), a leading international platform for well-established branded medicines, announces the successful placement of senior secured notes with a total volume of €750m. The proceeds from the new bonds will be used to finance the acquisition of the worldwide[1] commercial rights for Zyprexa® from Eli Lilly and [ … ]
Fri, 28.04.2023
Cheplapharm AG
CHEPLAPHARM Arzneimittel GmbH (“CHEPLAPHARM”), a leading international platform for well-established branded medicines, announces the successful placement of senior secured notes with a total volume of €750m. The proceeds from the new bonds will be used to finance the acquisition of the worldwide[1] commercial rights for Zyprexa® from Eli Lilly and [ … ]
Thu, 01.12.2022
Cheplapharm AG
Patrick König leaves CHEPLAPHARM at his own request
Klaus Köhl becomes new Chief Operating Officer
Patrick König leaves the Company at the end of the year at his own request.
Patrick König has worked for CHEPLAPHARM for a total of almost five years. In 2018, the business graduate started at the pharmaceutical company specializing in well-esta [ … ]